Astellas' eyes filings for menopause drug fezolinetant after...

Astellas looks to be in pole position to bring a new non-hormonal therapy for symptoms of menopause to market, after its candidate fezolinetant cleared a phase 3 safety study.

Bia Care starts NHS trial of its digital menopause platform

A virtual menopause clinic service developed by Bia Care is starting a randomised clinical trial within the NHS that will not only test how well it performs, but also attempt to tackle ineq

Update: Digital health firm Bia Care extends NHS menopause p...

Digital health startup Bia Care has been awarded additional funding from the NHS to extend the rollout of its virtual clinic providing remote care for women going through the menopause.

Bayer adds menopause drug to pipeline with KaNDy acquisition

Bayer is to buy UK-based KaNDy Therapeutics in a deal worth more than $800 million, adding the biotech’s menopause drug to its women’s health pipeline.

Astellas pushes non-hormonal menopause drug into phase 3